

## Highly Resistant Cholera Outbreak Strain in Zimbabwe

Tapfumanei Mashe, Daryl Domman, Andrew Tarupiwa, Portia Manangazira, Isaac Phiri, Masunda Kudzai, Prosper Chonzi, Elisabeth Njamkepo, Masindi Ramudzulu, Sekesai Mtapuri-Zinyowera, et al.

### ▶ To cite this version:

Tapfumanei Mashe, Daryl Domman, Andrew Tarupiwa, Portia Manangazira, Isaac Phiri, et al.. Highly Resistant Cholera Outbreak Strain in Zimbabwe. New England Journal of Medicine, 2020, 383 (7), pp.687-689. 10.1056/NEJMc2004773 . pasteur-02928196

### HAL Id: pasteur-02928196 https://pasteur.hal.science/pasteur-02928196v1

Submitted on 2 Sep 2020

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License

# 1 Highly drug-resistant cholera outbreak strain in Zimbabwe, 2018 - 2019

2	
3 4	Mashe Tapfumanei*, MSc Ministry of Health and Child Care, Zimbabwe
5 6 7	Daryl Domman*, Ph.D University of New Mexico Health Sciences Center, Albuquerque, New Mexico, USA
8 9 10	Tarupiwa Andrew, MSc Ministry of Health and Child Care, Zimbabwe
10 11 12 13 14	Manangazira Portia, M.D., M.P.H Phiri Isaac, M.D., M.P.H Ministry of Health and Child Care, Zimbabwe
15 16 17 18	Masunda Kudzai, M.D., M.P.H Chonzi Prosper, M.D., M.P.H Beatrice Road Infectious Diseases Hospital, Harare, Zimbabwe
19 20 21	Elisabeth Njamkepo, Ph.D Institut Pasteur, Paris, France
22 23 24	Masindi Ramudzulu, B.Sc (Hons) National Institute for Communicable Diseases, South Africa
25 26 27	Mtapuri-Zinyowera Sekesai <sup>‡</sup> , Ph.D Ministry of Health and Child Care, Zimbabwe
28 29 30	Anthony Marius Smith <sup>‡</sup> , Ph.D, National Institute for Communicable Diseases, South Africa
31 32 33	François-Xavier Weill <sup>‡</sup> , M.D., Ph.D Institut Pasteur, Paris, France
34 35 36 37	<b>Corresponding author</b> : F-X.W., Unité des Bactéries Pathogènes Entériques, Institut Pasteur, 28 rue du Dr Roux, 75015 Paris, France, <u>francois-xavier.weill@pasteur.fr</u> , Tel +33 1 45688345
38	*These authors contributed equally; $^{\ddagger}$ these authors jointly supervised this work
39	
40	Key words: Cholera, antimicrobial resistance, whole genome sequencing, Zimbabwe
41 42	Word count: 507.
43	

44

TO THE EDITOR: From 6 September 2018 to 26 March 2019, Zimbabwe experienced a 45 46 large cholera outbreak with 10,730 suspected cholera cases and 68 deaths (Fig. S1). Antimicrobial susceptibility data available on 65% (241/371) of the confirmed cases 47 showed that the Vibrio cholerae O1 serotype Ogawa isolates were multidrug resistant, 48 with unexpectedly high-level resistance to ciprofloxacin (96.7%, 233/241) and 49 ceftriaxone (99.6%, 240/241). Details of the methods are provided in the Supplementary 50 51 Appendix, available with the full text of this letter at NEJM.org. We sequenced the 52 whole-genomes of 11 V. cholerae O1 isolates - including ten collected during the cholera outbreak in Zimbabwe, and one originating from a South African patient with 53 travel history to Zimbabwe (Fig. S1, Table S1) - to investigate the determinants of 54 55 antimicrobial resistance as well as their phylogenetic relationships to >1,200 global seventh cholera pandemic V. cholerae El Tor (7PET) genomes.<sup>1,2</sup> Phylogenomic 56 analyses show that the 11 studied genomes belonged to sublineage T13 of the 7PET 57 58 lineage (Figs 1A and 1B, Table S2). Sublineage T13 was recently introduced from South Asia into East Africa and from there to Yemen (Figs 1B and 1C).<sup>2</sup> The T13 59 60 isolates were previously shown to have a narrow antimicrobial resistance (AMR) pattern, mostly due to a ~10-kb deletion in the SXT/R391 genomic island (called 61 ICE VchInd5), resulting in the loss of four AMR genes.<sup>2</sup> However, the 2018 Zimbabwean 62 isolates differed from previous T13 isolates by having 14 additional antimicrobial 63 64 resistance (AMR) genes carried on a ~160 kb IncA/C2 plasmid, leading to a broader resistance profile (Fig. S2, Tables S3-S4). In particular, the isolates were intermediately 65 resistant or resistant to tetracycline (presence of the tet(A) gene), intermediately 66 67 resistant or resistant to ciprofloxacin (mutations of the gyrA and parC genes and presence of the aac6'-lb-cr gene) and produced a CTX-M-15 extended spectrum beta-68

2

69 lactamase. Antibiotics such as tetracyclines, macrolides, and fluoroquinolones are 70 commonly used in the treatment of moderate-to-severe cholera cases - as an adjunct to rehydration therapy - to shorten the duration and volume of diarrhea, thereby limiting 71 bacterial transmission.<sup>3</sup> However, beta-lactams are not. Resistance to extended-72 spectrum cephalosporins (ESCs) is uncommon in 7PET isolates, and only ESC-73 resistant (ESC<sup>R</sup>) 7PET isolates from sporadic or small outbreak cases were observed in 74 Africa before 2018.<sup>1</sup> It is noteworthy that a large typhoid outbreak (> 3000 suspected 75 cases) caused by a ciprofloxacin-resistant strain - requiring the use of ESCs - occurred 76 in Harare between October 2017 – February 2018.<sup>4,5</sup> This might have contributed to the 77 ESC<sup>R</sup> patterns seen among the cholera outbreak strain several months later. 78

The 2018 Zimbabwean isolates were susceptible to azithromycin, which was consequently used to treat severe cholera cases during the outbreak. However, azithromycin resistance genes, such as mph(A) or mph(E) were sporadically identified in CTX-M-15-producing 7PET isolates collected in Zimbabwe (Table S4), the Democratic Republic of the Congo<sup>1</sup>, and Kenya<sup>2</sup> from 2010 to 2015. The acquisition of an IncA/C2 plasmid carrying both *mph* and *tet* genes by this T13 7PET strain would jeopardize the oral antibiotic treatment of cholera.

We emphasize the need for cross-border collaboration and continued laboratory
surveillance to stemming this highly-drug resistant T13 cholera strain in Africa.

- 88
- 89
- 91

90

- 92
- 93

3

#### 94 **References**

- 95
   1. Weill FX, Domman D, Njamkepo E, et al. Genomic history of the seventh pandemic
   96
   of cholera in Africa. Science 2017;358:785-9.
- 97
  2. Weill FX, Domman D, Njamkepo E, et al. Genomic insights into the 2016–2017
  98 cholera epidemic in Yemen. Nature 2019;565:230-3.
- 3. Leibovici-Weissman Y, Neuberger A, Bitterman R, et al. Antimicrobial drugs for
  treating cholera. Cochrane Database Syst Rev 2014;19;CD008625.
- N'cho HS, Masunda KPE, Mukeredzi I, et al. Notes from the field: typhoid fever
   outbreak—Harare, Zimbabwe, October 2017–February 2018. MMWR Morb Mortal
   Wkly Rep 2019;68:44-5.
- 104 5. Mashe T, Gudza-Mugabe M, Tarupiwa A, et al. Laboratory characterisation of
   105 Salmonella enterica serotype Typhi isolates from Zimbabwe, 2009-2017. BMC
   106 Infect Dis 2019;19:487.

107



108

#### 109 Legend to Figure

Phylogenetic relatedness of the V. cholerae O1 EI Tor isolates from the 2018 outbreak 110 in Zimbabwe. a, Maximum likelihood phylogeny of 1,213 genomic sequences. A6 was 111 112 used as an outgroup. The scale bar denotes substitutions per variable site (SNVs). 113 Branches are colored according to geographic location, inferred by stochastic mapping of the geographic origin of each isolate onto the tree. The inferred introduction events 114 115 into Africa are indicated by the letter 'T'. One branch was artificially shortened and as 116 denoted by the hash mark. b, Maximum clade credibility tree produced with BEAST for a subset of 92 representative isolates of the distal part of genomic wave 3 (i.e., those 117 118 with the *ctxB7* allele). Geographic location of the isolates is indicated in the same colors 119 as in panel **a**. Selected nodes supported by bootstrap values  $\geq$  0.95 are shown. 120 Acquisition of the multidrug-resistant plasmid is shown **c**, The geographical distribution

121	of selected 7PET sublineages T10 - T13. The date ranges shown for introductions are
122	the 95% credible interval estimate of the MRCA in years. Dashed lines do not represent
123	precise routes of transmission.
124	
125	